This database contains 67 studies, archived under the term: "Journal Of Alzheimer's Disease: JAD"
Click here to filter this large number of results.
A combination of CSF tau ratio and midsaggital midbrain-to-pons atrophy for the early diagnosis of progressive supranuclear palsy
Borroni, Barbara,
Malinverno, Matteo,
Gardoni, Fabrizio,
Grassi, Mario,
Parnetti, Lucilla,
Agosti, Chiara,
Alberici, Antonella,
Premi, Enrico,
Bonuccelli, Ubaldo,
Gasparotti, Roberto,
Calabresi, Paolo,
Di Luca, Monica,
Padovani, Alessandro
Cerebrospinal fluid (CSF) tau ratio decrease (33kDa/55kDa forms) and mid-saggital midbrain-to-pons (MP) atrophy have been suggested as diagnostic markers for progressive supranuclear palsy (PSP). The usefulness of their combined evaluation has never been tested. We evaluated the CSF tau ratio and the MP atrophy as a combined marker for early identification of PSP. A total […]
Risk of incident dementia in drug-untreated arterial hypertension: a population-based study
Bermejo-Pareja, Félix,
Benito-León, Julián,
Louis, Elan D.,
Trincado, Rocío,
Carro, Eva,
Villarejo, Alberto,
de la Cámara, Agustín Gómez
Arterial hypertension in midlife may increase the risk of late-life dementia. Notably, there is conflicting data as to whether hypertension in the elderly (age 65 years and older) is a risk factor for dementia and Alzheimer’s disease (AD). We determined whether drug-untreated hypertension was associated with a higher risk of incident dementia and AD. In […]
Prediction of amyloid-β pathology in amnestic mild cognitive impairment with neuropsychological tests
Bahar-Fuchs, Alex,
Villemagne, Victor,
Ong, Kevin,
Chetélat, Gaël,
Lamb, Fiona,
Reininger, Cornelia B.,
Woodward, Michael,
Rowe, Christopher C.
Assessment of disease biomarkers, particularly the in vivo assessment of amyloid-β (Aβ) burden with positron emission tomography (PET), is gradually becoming central to the diagnosis of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD). However, the incorporation of biomarker evidence to the diagnostic process is currently restricted mainly to research settings. The identification of […]
Measuring memory in large group settings using a continuous recognition test
Memory function generally deteriorates with age, and memory impairments are a common symptom of serious illness such as dementia. Although screening tests are widely used throughout Medicine, they are not yet commonly used to detect memory impairments. The objective of this study was to characterize an audience-based memory test suitable for administration to a large […]
The role of neuropsychology in distinguishing the posterior cortical atrophy syndrome and Alzheimer’s disease
This study investigated the neuropsychological hallmarks of posterior cortical atrophy (PCA). Seventeen patients with PCA, 17 patients with probable Alzheimer’s disease (PAD), and 17 healthy age-matched subjects underwent neuropsychological testing for abstract reasoning, visuospatial abilities, memory, language, executive functions, praxes, and attention. The PCA patients were significantly more impaired in visual perception, spatial memory, visual […]
Lipid lowering agents, cognitive decline, and dementia: the three-city study
Ancelin, Marie-Laure,
Carrière, Isabelle,
Barberger-Gateau, Pascale,
Auriacombe, Sophie,
Rouaud, Olivier,
Fourlanos, Spiros,
Berr, Claudine,
Dupuy, Anne-Marie,
Ritchie, Karen
The aim of this prospective cohort study was to evaluate the effects of lipid lowering agent (LLA) intake on cognitive function in 6,830 community-dwelling elderly persons. Cognitive performance (global cognitive functioning, visual memory, verbal fluency, psychomotor speed, and executive function), clinical diagnosis of dementia, and fibrate and statin use, were evaluated at baseline, and 2, […]
Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in Alzheimer’s disease patients
Albani, Diego,
Martinelli Boneschi, Filippo,
Biella, Gloria,
Giacalone, Giacomo,
Lupoli, Sara,
Clerici, Francesca,
Benussi, Luisa,
Ghidoni, Roberta,
Galimberti, Daniela,
Squitti, Rosanna,
Mariani, Stefania,
Confaloni, Annamaria,
Bruno, Giuseppe,
Mariani, Claudio,
Scarpini, Elio,
Binetti, Giuliano,
Magnani, Giuseppe,
Franceschi, Massimo,
Forloni, Gianluigi
Alzheimer’s disease (AD) is a neurodegenerative disorder often treated with donepezil, an acetylcholinesterase inhibitor. Response to donepezil is variable, probably based on patients’ genetic background in donepezil metabolizing enzymes, including cytochrome 2D6 (CYP2D6). We evaluated the association between clinical response to donepezil and a common variant (rs1080985) of CYP2D6, previously reported to be associated with […]